VivoSeq
Other

Hyperplasia

31

Pipeline Programs↗

9

Active Trials↗

18

Companies Involved↗

Hyperplasia is a moderately active landscape with 31 programs across 18 companies. The most active players are EMD Serono, Otsuka, Bayer. 5 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

80/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Phase 1Otsuka logo

Otsuka

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2Eli Lilly logo

Eli Lilly

3 programs

Phase 2Sanofi logo

Sanofi

1 program

Phase 3Novartis logo

Novartis

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

35 of 38 classified programs — the dominant modality here.

8%ALL OTHERSPeptide38%

Small molecule leads; the ring shows all 38 classified programs, each share of the total. Modality classified for 100% of 38 pipeline programs.

Analysis

Trial Status

29

clinical trials

Completed12 · 41%
Unknown status5 · 17%
Recruiting5 · 17%
Not yet recruiting3 · 10%
Withdrawn2 · 7%
Terminated1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

29 trials

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
Recruiting·—·Phase 2/3·NCT05316493·172 enrolled
Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
Recruiting·Tasly Pharmaceutical Group Co., Ltd logoTasly Pharmaceutical Group Co., Ltd·Phase 3·NCT06685978·430 enrolled
Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia
Recruiting·UUniversity of Michigan·Phase 4·NCT06840470·40 enrolled
Efficacy of Methylprednisolone Pulses in Neuroendocrine Celles Hyperplasia of Infancy : An Early Phase Study
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06471556·18 enrolled
Clinical Efficacy of Chlorhexidine Varnish in Reducing Gingival Hyperplasia, Plaque Accumulation, and White Spot Lesions in Orthodontic Patients
Recruiting·KKhyber Medical University Peshawar·N/A·NCT07115784·22 enrolled
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
Active, not recruiting·—·Phase 2/3·NCT06390904·29 enrolled
Clinical Study on the Treatment of Breast Hyperplasia With Kou Sha Therapy Based on Real World
Not yet recruiting·—·N/A·NCT06310538·60 enrolled
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium
Not yet recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06073184·71 enrolled
Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia
Not yet recruiting·UUniversity of Manitoba·Phase 3·NCT07017452·48 enrolled
A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia
Completed·UUniversity Hospital of North Norway·Phase 4·NCT01074892·170 enrolled
Genistein and Endometrial Hyperplasia
Completed·UUniversity of Messina·Phase 2·NCT00453960·59 enrolled
Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia
Completed·KKayseri Education and Research Hospital·Phase 4·NCT02872818·40 enrolled
Superb Microvascular Imaging in Focal Nodular Hyperplasia
Completed·SSamsung Medical Center·N/A·NCT02737865·62 enrolled
Effects of Isoflavone in Patients With Watchful Waiting Benign Prostate Hyperplasia
Completed·—·N/A·NCT00861588·176 enrolled
A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia
Completed·Astellas logoAstellas·Phase 2·NCT02038868·320 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)